Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) plus regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC)

Affiliation auteurs!!!! Error affiliation !!!!
TitreEfficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) plus regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC)
Type de publicationJournal Article
Year of Publication2017
AuteursFogelman DR, Bendell JC, Cubillo A, Alfonso PGarcia, Miron MLuisa Limo, Nemunaitis JJ, Flora DBlake, Borg C, Mineur L, Vieitez JM, Cohn ALee, Saylors GBrian, Assad A, Switzky JC, O'Neill P, Zhou L, Kochenderfer MD
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume35
Date PublishedFEB 1
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2017.35.4_suppl.663